InMed Pharmaceuticals Inc
INM1.230USD
-0.030-2.38%
收盘 12/24, 13:00（美东）报价延迟15分钟
3.20M总市值
0.03市盈率 TTM
关于 InMed Pharmaceuticals Inc 公司
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
InMed Pharmaceuticals Inc简介
公司代码INM
公司名称InMed Pharmaceuticals Inc
上市日期Jun 21, 2001
CEOAdams (Eric A)
员工数量- -
证券类型Ordinary Share
年结日Jun 21
公司地址1445-885 West Georgia St.
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编V6C 3E8
电话16046697207
网址https://www.inmedpharma.com/
公司代码INM
上市日期Jun 21, 2001
CEOAdams (Eric A)
InMed Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Sabby Management, LLC
7.85%
Yorkville Advisors Global, LP.
2.87%
DRW Securities, LLC
1.28%
Virtu Americas LLC
0.73%
Renaissance Technologies LLC
0.60%
其他
86.68%
持股股东
持股股东
占比
Sabby Management, LLC
7.85%
Yorkville Advisors Global, LP.
2.87%
DRW Securities, LLC
1.28%
Virtu Americas LLC
0.73%
Renaissance Technologies LLC
0.60%
其他
86.68%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
10.71%
Investment Advisor
1.64%
Research Firm
0.74%
Hedge Fund
0.60%
Individual Investor
0.15%
其他
86.16%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
30
135.23K
4.82%
+48.77K
2025Q2
37
127.03K
6.34%
+18.71K
2025Q1
34
127.03K
10.75%
+32.44K
2024Q4
33
169.52K
14.04%
+76.54K
2024Q3
35
65.17K
63.92%
+11.73K
2024Q2
34
30.10K
7.60%
-6.51K
2024Q1
33
42.40K
13.49%
-1.13K
2023Q4
31
40.41K
15.37%
-91.29K
2023Q3
32
1.59K
1.33%
-12.58K
2023Q2
37
1.04K
0.99%
-13.60K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Sabby Management, LLC
36.13K
1.52%
+20.77K
+135.22%
Dec 31, 2024
Yorkville Advisors Global, LP.
80.37K
3.37%
+80.37K
--
Dec 13, 2024
Adams (Eric Ashley)
2.20K
0.09%
-5.70K
-72.17%
Jun 30, 2025
Hull (Andrew Harold)
1.91K
0.08%
-425.00
-18.19%
Jun 30, 2025
SBI Securities Co., Ltd.
300.00
0.01%
--
--
Jun 30, 2025
Banque Cantonale Vaudoise
6.00
0%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
AdvisorShares Pure Cannabis ETF
0%
AdvisorShares Pure Cannabis ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
公告日期
类型
比率
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
常见问题
InMed Pharmaceuticals Inc的前五大股东是谁？
InMed Pharmaceuticals Inc 的前五大股东如下：
Sabby Management, LLC持有股份：36.13K，占总股份比例：1.52%。
Yorkville Advisors Global, LP.持有股份：80.37K，占总股份比例：3.37%。
Adams (Eric Ashley)持有股份：2.20K，占总股份比例：0.09%。
Hull (Andrew Harold)持有股份：1.91K，占总股份比例：0.08%。
SBI Securities Co., Ltd.持有股份：300.00，占总股份比例：0.01%。
Sabby Management, LLC持有股份：36.13K，占总股份比例：1.52%。
Yorkville Advisors Global, LP.持有股份：80.37K，占总股份比例：3.37%。
Adams (Eric Ashley)持有股份：2.20K，占总股份比例：0.09%。
Hull (Andrew Harold)持有股份：1.91K，占总股份比例：0.08%。
SBI Securities Co., Ltd.持有股份：300.00，占总股份比例：0.01%。
InMed Pharmaceuticals Inc的前三大股东类型是什么？
InMed Pharmaceuticals Inc 的前三大股东类型分别是：
Sabby Management, LLC
Yorkville Advisors Global, LP.
DRW Securities, LLC
Sabby Management, LLC
Yorkville Advisors Global, LP.
DRW Securities, LLC
有多少机构持有InMed Pharmaceuticals Inc(INM)的股份？
截至2025Q3，共有30家机构持有InMed Pharmaceuticals Inc的股份，合计持有的股份价值约为135.23K，占公司总股份的4.82%。与2025Q2相比，机构持股有所增加，增幅为-1.52%。
哪个业务部门对InMed Pharmaceuticals Inc的收入贡献最大？
在--，--业务部门对InMed Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
